While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

Friday, Aurora Therapeutics debuted with $16 million in seed capital from Menlo Ventures. Its goal: To develop the industry’s ...

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a ...

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P.

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

The closure, broken by Endpoints News on Thursday after speaking with two former employees, appears to have officially ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...